Jennifer King Email

Senior Director, Early Development and Clinical Pharmacology . Cyclerion

Current Roles

Employees:
18
Revenue:
$3.5M
About
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.
Cyclerion Address
245 First Street
Cambridge, MA
United States
Cyclerion Email

Past Companies

Tisento TherapeuticsSenior Director, Clinical Pharmacology, DMPK and Toxicology
CyclerionSenior Director, Clinical Pharmacology, DMPK and Toxicology
CyclerionSenior Director, Clinical Pharmacology

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.